0001209191-21-005547.txt : 20210126
0001209191-21-005547.hdr.sgml : 20210126
20210126202401
ACCESSION NUMBER: 0001209191-21-005547
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210124
FILED AS OF DATE: 20210126
DATE AS OF CHANGE: 20210126
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Macrae Sandy
CENTRAL INDEX KEY: 0001675687
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 21556387
MAIL ADDRESS:
STREET 1: 721 ST. GEORGES ROAD
CITY: PHILADELPHIA
STATE: PA
ZIP: 19119
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-24
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001675687
Macrae Sandy
C/O SANGAMO THERAPEAUTICS, INC.
7000 MARINA BLVD
BRISBANE
CA
94005
1
1
0
0
President and CEO
Common Stock
2021-01-24
4
F
0
3977
14.95
D
244002
D
Represents shares of common stock underlying the portion of the restricted stock unit ("RSU") grant surrendered by the Reporting Person to the Issuer for tax withholding upon settlement of such RSU grant on January 24, 2021, using the Issuer's closing stock price on January 22, 2021 of $14.95/share, pursuant to the terms of the Issuer's 2013 Stock Incentive Plan.
Includes 6,523 shares common stock issued on January 24, 2021 upon settlement of Reporting Person's January 24, 2018 RSU grant. Additionally this amount includes: 42,168 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2019, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"); and
168,750 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2020 pursuant to the terms of the Issuer's Amended and Restated 2018 EIP, as amended. All such RSUs vest with respect to 1/3rd of the shares in each respective RSU grant in three equal annual installments over the three-year period measured from the dates of grant, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended.
/s/ Matthew Colvin, Attorney-in-Fact for Sandy Macrae
2021-01-26